Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas.
Brodin BA, Wennerberg K, Lidbrink E, Brosjö O, Potdar S, Wilson JN, Ma L, Moens LN, Hesla A, Porovic E, Bernhardsson E, Papakonstantinou A, Bauer H, Tsagkozis P, von Sivers K, Wejde J, Östling P, Kallioniemi O, Stragliotto CL.
Brodin BA, et al. Among authors: bauer h.
Br J Cancer. 2019 Feb;120(4):435-443. doi: 10.1038/s41416-018-0359-4. Epub 2019 Feb 12.
Br J Cancer. 2019.
PMID: 30745580
Free PMC article.